PUBLISHER: Grand View Research | PRODUCT CODE: 1301173
PUBLISHER: Grand View Research | PRODUCT CODE: 1301173
The global controlled release drug delivery market size is expected to reach USD 110.13 billion by 2030, registering a CAGR of 10.6% according to a new report by Grand View Research, Inc. The benefits associated with controlled release drug delivery systems such as increased therapeutic efficacy, fewer side effects, and low treatment cost are the factors driving the growth of the market during the forecast period. These technologies offer various benefits over traditional delivery forms. Reduced dosage and dosage frequency, enhanced patient compliance, less gastrointestinal side effects, uniform drug effect, improved drug efficacy and safety, and reduced fluctuation of plasma drug levels are some of the major advantages offered by controlled release technology.
The presence of multiple in-vivo biological barriers that affect the absorption, bioavailability, and stability of the drug has opened a wide horizon for controlled release drug delivery products. For instance, a controlled release drug delivery system has enabled the delivery of even large and complex molecules such as DNA/RNA, proteins, and polypeptides. Additionally, the rising awareness among healthcare professionals, regarding the advantage of controlled release drug delivery systems over conventional systems is expected to drive the demand for the market in long run.
The rapidly increasing geriatric and pediatric population is one of the major factors impacting the growth of the market. Since a major proportion of prescription non-adherence cases is observed in this age group of the population. Innovations in various drug delivery systems have been providing the geriatric and pediatric populations with easy solutions, which are further propelling the market. Controlled release of drugs allows a reduction in overdose in the elderly population as they can be altered according to the required dosage over a specific period of time.